Systemische Therapie des metastasierten Mammakarzinoms

  • V. Möbus
  • R. Kreienberg
Part of the Onkologie Aktuell book series (ONKAKTUELL)

Zusammenfassung

Bis heute gilt das Dogma, dass das metastasierte Mammakarzinom nicht mehr kurativ behandelt werden kann. Die mittlere Überlebenszeit nach Feststellung der Metastasierung beträgt im Median 2 Jahre. Sie ist etwas länger bei Patientinnen, deren Tumor hormonrezeptorpositiv ist oder die eine klinisch komplette Remission unter konventioneller Chemotherapie erzielen. Beim Nachweis viszeraler Metastasen ist die Prognose deutlich ungünstiger als bei einer ausschließlichen Knochen- oder Weichteilmetastasierung, was in den Therapieempfehlungen des Possinger-Score Berücksichtigung findet. Ob das Dogma der Inkurabilität, z. B. durch den Einsatz der Hochdosischemotherapie für ein zu definierendes Kollektiv, aufgehoben werden kann, ist unwahrscheinlich.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Acuna LR, Langhi M, Pérez J et al. (1999) Vinorelbine and Pac-litaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 17: 74–81Google Scholar
  2. Australian New Zealand Breast Cancer Trials Group (1986) A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 4:186–193Google Scholar
  3. Barni S, Frontin L, Villa S et al. (1993) Vinorelbine (VNR) in pretreated advanced breast cancer (ABC). Eur J Cancer 29 A (suppl 6): 418 (abstr)Google Scholar
  4. Batist G, Ramakrishnan G, Sekhar Rao C et al. (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cnacer. J Clin Oncol 19:1444–1454PubMedGoogle Scholar
  5. Berlie J, Meeus L, Meyer C et al. (1990) Protracted continuous infusion of 5-fluorouracil among breast cancer patients. Proc Am Soc Clin Oncol 9:40 (abstr)Google Scholar
  6. Bezwoda WR, Seymour L, Dansey RD (1995) High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13: 2483–2489PubMedGoogle Scholar
  7. Biganzoli L, Cufer T, Bruning P, Coleman R et al. (2000) Doxorubicin (A)/Taxol (T) versus Doxorubicin/Cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. Proc Am Soc Clin Oncol 19:282 (abstract)Google Scholar
  8. Blum JL, Jones SE, Buzdar AU et al. (1999) Multicenter phase II study of Capecitabine in Paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493PubMedGoogle Scholar
  9. Bonneterre J, Thürlimann B, Robertson JFR et al. (2000) Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. Journal of Clinical Oncology 18 (22): 3748–3757PubMedGoogle Scholar
  10. Buchanan RB, Blaney RW, Durant KR et al. (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326–1330(1986)PubMedGoogle Scholar
  11. Burstein HJ, Manola J, Younger J et al. (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212–1219PubMedGoogle Scholar
  12. Buzdar A, Jonat W, Howell A et al, Arimidex Study Group (1996) Anastrozole, a potent and selective aromatase inhibitor, versus Megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 14/7:2000–2011PubMedGoogle Scholar
  13. Buzdar A, Jonat W, Howell A, Yin H, Lee D, Arimidex International Study Group (1997a) Significant improved survival with Arimidex (Anastrozole) versus Megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials. Proc Am Soc Clin Oncol 16:156a (Abstr 545) (33rd Ann Meeting Am Soc Clin Oncol ASCO, Denver 1997)Google Scholar
  14. Buzdar AU, Jones SE, Vogel CL, Walter J, Plourde P, Webster A, Arimidex Study Group (1997b) A phase III trial comparing Anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with Megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 79/4: 730–739PubMedCrossRefGoogle Scholar
  15. Carmichael J, Walling J (1996) Phase II activity of Gemcitabine in advanced breast cancer. Sem Oncol 23:77–81Google Scholar
  16. Catimel G, Spielmann M, Dieras V et al. (1996) Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety. Semin Oncol 23 (1, Suppl 1): 24–27PubMedGoogle Scholar
  17. Chan S, Friedrichs K, Noel D et al. (1999) Prospective randomized trial of Docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341–2354PubMedGoogle Scholar
  18. Chang AY, Most C, Pandya KH (1982) Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer. Am J Clin Oncol 12: 453–455CrossRefGoogle Scholar
  19. Chevallier B, Fumoleau P, Kerbrat P et al. (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314–322PubMedGoogle Scholar
  20. Cobleigh MA, Vogel C, Tripathy D et al. (1998) Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 17:376Google Scholar
  21. Conte PF, Michelotti A, Baldini E et al. (1996) Epirubicin plus paclitaxel, a highly active combination devoid of significant cardiotoxicity in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 15:118 (Abstract 138)Google Scholar
  22. Degardin M, Bonneterre J, Hecquet B et al. (1994) Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5:423–426PubMedGoogle Scholar
  23. DelMastro L, Venturini M, Lionetto R et al. (1997) Randomized phase III trial evaluating the role of erythrpoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15: 2715–2721Google Scholar
  24. Dieras V, Barthier S, Beuzeboc P et al. (1998) Phase II study of docetaxel in combination with doxorubicin as 1st line chemotherapy of metastatic breast cancer. Breast Cancer Res Treat 50:262 (abstract)Google Scholar
  25. Dieras V, Fumoleau P, Chevallier B et al. (1994) Second EORTC-Clinical Screening group (CSG) phase II trial of taxotere (docetaxel) as first line chemotherapy (CT) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 13:78 (abstr)Google Scholar
  26. Dogliotti L, Gorzegno G, Bau MG et al. (1993) Vinorelbine as second line treatment in anthracycline pre-treated advanced breast cancer patients: a phase II study. Eur J Cancer 29 A (suppl 6): 430 (abstr)Google Scholar
  27. Dombernowsky P, Smith I, Falkson G et al. (1998) Letrozole a new aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453–461PubMedGoogle Scholar
  28. Dowsett M, Welch H, Blackman GM, King N, Howell A, Tobias JS, Baum M (1997) A randomized, double blind, parallelgroup trial to evaluate the effect of Arimidex (Anastrozole) on the pharmacokinetics of Tamoxifen in postmenopausal breast cancer patients. Breast 6/4: 245 (Abstr 0–74)Google Scholar
  29. Focan C, Andrien JM, Closon MTh et al. (1993) Dose-response relationship of Epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253–1263PubMedGoogle Scholar
  30. Fumoleau P, Chevallier B, Kerbrat P et al. (1993) First line chemotherapy with taxotere (T) in advanced breast cancer (ABC): A phase II study of the EORTC clinical screening group (CSG). Proc Am Soc Clin Oncol 12:56 (abstr)Google Scholar
  31. Gamucci T, Piccart M, Bruning P et al. (1998) Single agent taxol versus doxorubicine as first-line chemotherapy in advanced breast cancer. Final results of an EORTC randomized study with crossover. Proc Am Soc Clin Oncol 17:428 (abstract)Google Scholar
  32. Gasparini G, Caffo O, Barni S et al. (1994) Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 12:2094–2101PubMedGoogle Scholar
  33. Gelber RD and Goldhirsch A for the Ludwig Breast Cancer Study Group (1986) A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4:1772–1779PubMedGoogle Scholar
  34. Gianni L, Munzone E, Capri G et al. (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose- and sequence-finding study. J Clin Oncol 13: 2688–2699PubMedGoogle Scholar
  35. Glaspy J, Bukowski R, Steinberg D et al. (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218–1234PubMedGoogle Scholar
  36. Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197–2205PubMedGoogle Scholar
  37. Hansen R, Quebbeman E, Beatty P (1987) Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast. Cancer Res Treat 10:145–149CrossRefGoogle Scholar
  38. Holmes FA (1996) Update: The M.D. Anderson Cancer Center Experience with paclitaxel in the management of breast carcinoma. Semin Oncol 22 (Suppl 8): 9–15Google Scholar
  39. Hoogstraten B, Fletcher WS, Gad EL et al. (1982) Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: A Southwest Oncology Group study. Cancer Res 42:4788–4791PubMedGoogle Scholar
  40. Hortobagyi GN, Porter L, Blayney D et al. (1996) Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT), by monthly pamidronate sodium (PAM) (Aredia®) infusion. Proc Am Soc Clin Oncol 15:99 (abstract)Google Scholar
  41. Huan S, Pazdur R, Singhakowinta A (1989) Low dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma. Cancer 63:419–422PubMedCrossRefGoogle Scholar
  42. Hudis CA, Scidman AD, Crown JPA et al. (1996) Phase II and pharmacological study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14: 58–65PubMedGoogle Scholar
  43. Ingle JN, Krook JE, Green SJ et al. (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 876–882Google Scholar
  44. Jabboury K, Holmes FA, Hortobagyi G (1989) 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64: 793–797PubMedCrossRefGoogle Scholar
  45. Jackson IM, Litherland S, Wakeling AE (1991) Tamoxifen and other antiestrogens. In: Powles TJ, Smith IE (eds) Medical management of breast cancer. London: Martin Dunitz: 51–61Google Scholar
  46. Jonat W, Howell A, Blomqvist C et al. on behalf of the ARIMIDEX Study Group (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor Anastrozole (Arimidex) with Megestrol Acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32 A: 404–412CrossRefGoogle Scholar
  47. Jones S, Winer L, Vogel C et al. (1994) A multicenter, randomized trial of IV Nabelbine vs IV Alkeran in patients with anthracycline-refractory advanced breast cancer (ABC). Proc Am Soc Clin Oncol 13: 216 (abstr)Google Scholar
  48. Kaufmann M, Bajetta E, Dirix LY et al. (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. J Clin Oncol 18 (7): 1399–1411PubMedGoogle Scholar
  49. Kaufmann M, Jonat W, Kleeberg U et al. (1989) Goserelin, a depot gonadotropin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7:1113–1119PubMedGoogle Scholar
  50. Kaufmann M, Jonat W, Schachner-Wunschmann E, Bastert G, Maass H (1991) The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer — a 5 year experience and further endocrine therapies. Cooperative German Zoladex Study Group. Onkologie 14: 22–30PubMedCrossRefGoogle Scholar
  51. Klijn JGM, Blarney RW, Boccardo F et al. (1998) On behalf of CHAT: a new standard treatment for advanced premenopausal breast cancer: a meta-analysis of the combined hormonal agent trialists group (CHAT). Europ J Cancer 34 (Suppl. 5): 405–410Google Scholar
  52. Lalisang R, Wils J, Nortier J et al. (1996) Dose intensification of epirubicin and paclitaxel with G-CSF support in metastatic breast cancer. Proc ASCO 15:99 (abstract 62)Google Scholar
  53. Lipton A, Leff R, Gluck S et al. (1996) Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly Pamidronate sodium (Aredia)®) infusion. Proc Am Soc Clin Oncol 15:152 (abstract)Google Scholar
  54. Littlewood TJ, Rapaport B, Bajetta E, Nortier J (2000): Possible relationship of hemoglobin levels with survival in anemic cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol 19, 2381 (abstract)Google Scholar
  55. Lokich JL, Anderson N (1993) Infusional chemotherapy for breast cancer. The Cancer Center of Boston. J Inf Chemother 3:9–14Google Scholar
  56. Lotz JP, Curé H, Janvier M et al. (1999) High-dose chemotherapy (HD-CT) with hematopoietic stem cells transplantation (HSCT) for metastatic breast cancer (MBC): Results of the French protocol PEGASE 04. Proc Am Soc Clin Oncol 18:161 (abstract)Google Scholar
  57. Lück H J, Thomssen C, duBois A et al. (1996) Phase II study of paclitaxel and 4-epi-doxorubicin (epirubicin) as first-line therapy in patients with metastatic breast cancer. Proc ASCO 15:120 (Abstract 147)Google Scholar
  58. Lück HJ, Thomssen C, Untch M et al. (2000) Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/Paclitaxel (ET) vs. Epirubicin/Cyclophosphamid (EC). A study of the AGO breast cancer group. Proc Am Soc Clin Oncol 19: 280 (abstract)Google Scholar
  59. Marty M, Extra JM, Dieras V et al. (1992) A review of the antitumor activity of vinorelbine in breast cancer. Drugs 44 (Suppl. 4): 29–35PubMedCrossRefGoogle Scholar
  60. Marty M (2001) Liposomal doxorubicin (Myocet™) and conventional anthracyclines: a comparison. The Breast (Suppl 2): 28–33CrossRefGoogle Scholar
  61. McCormack PM, Martini N (1979) The changing role of surgery for pulmonary metastases. Ann Thorac Surg 41: 833Google Scholar
  62. Miller WR (1996) Aromatase inhibitors. Endocr Rel Cancer 3/1: 65–79CrossRefGoogle Scholar
  63. Moiseyenko V, O’Reilly SM, Talbot DC et al. (1998) A randomized phase II study of Xeloda (Capecitabine) vs. Paclitaxel in breast cancer patients failing previous anthracycline therapy. Ann Oncol 9 (Suppl 4): 620 (abstract)Google Scholar
  64. Mountain CF, McMurtrey MJ, Hermes KE (1984) Surgery for pulmonary metastases: a 20 year experience. Ann Thorac Surg 38:323PubMedCrossRefGoogle Scholar
  65. Mouridsen H, Gershanovich M, Sun Y et al. (2001) Superior Efficacy of Letrozole Versus Tamoxifen as First Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer group. Journal of Clinical Oncology 19 (10): 2596–2606PubMedGoogle Scholar
  66. Nabholtz JM, Buzdar A, Pollak M et al. (2000) Anastrolzole Is Superior to Tamoxifen as First Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial. Journal of Clinical Oncology 18 (22): 3758–3767PubMedGoogle Scholar
  67. Nabholtz JM, Falkson G, Campos D et al. (1999) A phase III trial comparing Doxorubicin (D) and Docetaxel (T) (AT) to Doxorubicin and Cyclophosphamide (AC) as first line chemotherapy for MBC. Proc Am Soc Clin Oncol 18:485 (abstract)Google Scholar
  68. Nabholtz J-M, Gelmon K, Bontenbal M et al. (1996) Multicenter, randomized comparative study of two doses of Paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858–1867PubMedGoogle Scholar
  69. Nabholtz J-M, Senn HJ, Bezwoda WR et al. (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17:1413–1424PubMedGoogle Scholar
  70. Norton L, Slamon D, Leyland-Jones B et al. (1999) Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Her-ceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18: 483 (abstract)Google Scholar
  71. Pollow K, Kreienberg R, Juchem M, Hoffmann G (1993) Hochdosierte Medroxyprogesteronacetat (MPA)-Therapie beim fortgeschrittenen Mammakarzinom unter besonderer Berücksichtigung der MPA-Serumspiegel. Tumordiagn Ther 14:49–55Google Scholar
  72. Possinger K, Wagner H, Wilmanns W (1991) Chemotherapie des fortgeschrittenen Mammakarzinoms. Krankenhausarzt 64:101–109Google Scholar
  73. Possinger K, Wilmanns W (1993) Palliative Therapieführung zur Hemmung der Tumorprogression bei Patientinnen mit metastasierten Mammakarzinomen. Internist 34:340–350PubMedGoogle Scholar
  74. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN (1997) Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemootherapy in patients with metastatic breast cancer. J Clin. Oncol. 15:3171–3177PubMedGoogle Scholar
  75. Ranson M, Carmichael J, O’Byrne K et al. (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15:3185–3191PubMedGoogle Scholar
  76. Ravdin PM, Burris III HA, Cook G et al. (1995) Phase II trial of Docetaxel in advanced anthracycline-resistant or anthrace-nedione-resistant breast cancer. J Clin Oncol 13: 2879–2885PubMedGoogle Scholar
  77. Reichman BS, Scidman AD, Crown JPA et al. (1993) Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943–1951PubMedGoogle Scholar
  78. Rischin D, Millward MJ, Webster LK et al. (1996) Phase I study of paclitaxel and epirubicin in advanced cancer. Proc ASCO 15:480 (Abstract 1525)Google Scholar
  79. Sauer H (1996) Anwendung von Zytostatika. In: Tumorzentrum München (Hrsg) Empfehlungen zur Diagnostik, Therapie und Nachsorge — MammakarzinomeGoogle Scholar
  80. Schmid P and Possinger K (2001) Liposomal anthracyclines for improved cardiac tolerability. The Breast (Suppl 2): 22–27Google Scholar
  81. Seidman AD, Hudis CA, Albanel J et al. (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353–3361PubMedGoogle Scholar
  82. Seidman AD, Hudis C, Crown JPA et al. (1993) Phase II evaluation of taxotere (RP56976, NSC628503) as initial chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 12: 63 (abstr)Google Scholar
  83. Seidman AD, Reichman BS, Crown JPA et al. (1995) Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152–1159PubMedGoogle Scholar
  84. Sjöstrom J, Blomqvist C, Mouridsen H et al. (1999) Docetaxel compared with sequential methotrexate and 5-Fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194–1201PubMedCrossRefGoogle Scholar
  85. Slamon DJ, Clark GM, Wong SG et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 235:177–182PubMedCrossRefGoogle Scholar
  86. Sparano JA, Ju P, Schadfer PL et al. (1998) Phase II trial of doxorubicin and docetaxel plus granulocyte-colony stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Trial (E1196). Breast Cancer Res Treat 50:27 (abstract)CrossRefGoogle Scholar
  87. Spielman M, Dorval T, Turpin F et al. (1994) Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12:1764–1770Google Scholar
  88. Spielmann M, Llombart A, Zelek L et al. (1999) Docetaxel-cis-platin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol 10: 1457–1460PubMedCrossRefGoogle Scholar
  89. Stadtmauer EA, O’Neill A, Goldstein LJ et al. (1999) Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia Intergroup Study (PBT-i). Proc Am Soc Clin Oncol 18:1 (abstract)Google Scholar
  90. Staren ED, Salerno C, Rongione A, Witt RT, Faber P (1992) Pulmonary resection for metastatic breast cancer. Arch Surg 127:1282PubMedCrossRefGoogle Scholar
  91. Tannock IF, Boyd NF, DeBoer G et al. (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377–1387PubMedGoogle Scholar
  92. Taylor CW, Green S, Dalton WS et al. (Study Group) (1998) Multicenter randomized clinical trial of Goserelin versus surgical ovariectomy in premenopausal patients with receptor positive metastatic breast cancer: Intergroup Study. J Clin Oncol 16:994–999PubMedGoogle Scholar
  93. ten Bokkel Huinink W, Prove AM, Piccart M et al. (1994) A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5:527–532Google Scholar
  94. Theodoulou M, Campos S, Welles L et al. (2001) Safety and efficiacy of TLC D-99 (Myocet®) and Trastuzumab in patients with advanced breast cancer. European Journal of Cancer 37 (Suppl. 6), abstr # 712Google Scholar
  95. Trudeau ME, Eisenhauer E, Lofters W et al. (1993) Phase II study of taxotere as first line chemotherapy for metastatic breast cancer (MBC). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study. Proc Am Soc Clin Oncol 12: 64 (abstr)Google Scholar
  96. Valero V, Holmes FA, Walters RS et al. (1995) Phase II trial of Docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879–2885Google Scholar
  97. Valero V, Ravdin PM, Walters R et al. (1994) Taxotere® (docetaxel) in the treatment of anthracycline/anthracenedione-refractory metastatic breast cancer (ARMBC): combined results of 2 US phase II studies. 19th Meeting of the European Society of Medical Oncology (ESMO), LisbonGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • V. Möbus
  • R. Kreienberg

There are no affiliations available

Personalised recommendations